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Abstract 
 
Background: Prognosis of Japanese steroid-treated patients with cardiac sarcoidosis (CS) 
and factors affecting it are not yet determined.  Methods and Results: We examined 58 
consecutive CS patients who were admitted to our hospital from April 2002 to March 2012 
with a median follow-up period of 50 months to study their survival and the prognostic 
indicators of a composite endpoint including ventricular arrhythmias (VA), heart failure 
hospitalization, de novo device implantation and all-cause mortality.  There was no 
significant difference in baseline clinical characteristics between patients according to their 
initial steroid dose.  There were only two death events reported, and 5- and 10- years 
survival was 98% and 96% respectively.  Composite endpoint-free survival was 
significantly better in patients with preserved left ventricular ejection fraction (LVEF) at 
baseline and after 1 year of steroid therapy, as well as in patients with no evidence of late 
gadolinium enhancement on cardiac magnetic resonance imaging (LGE-CMRI) (P<0.001, = 
0.03, and < 0.01 respectively).  Multivariate analysis revealed that independent markers of 
poor composite outcome include depressed LVEF at baseline (HR= 2.2, P=0.04), and after 1 
year of treatment (HR=2.3, P=0.03), and VA at baseline (HR=2.9, P=0.02)  Conclusions: 
The prognosis of Japanese CS patients is improving, and impaired baseline LVEF, 
unfavorable LVEF course, the presence of VA, and positive LEG-CMRI are independent 
predictors of poor outcome in this population.                          
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Introduction 
 
Sarcoidosis is a multisystem disease that is histologically characterized by non-caseating 
granuloma formation in various organs.
1)
  Although sarcoidosis could affect any organ, including 
the lungs, skin, eyes, liver and lymphatics,
1,2)
  cardiac involvement is the most important 
prognostic factor.
3,4)
  The incidence of cardiac sarcoidosis (CS) has been reported to be ~2% 
among patients with sarcoidosis, however, previous autopsy studies demonstrated that cardiac 
involvement is relatively high (20~25%),
4,5)
  which has been recently confirmed by cardiac 
imaging.
6)
  Interestingly, CS is more common and seems to carry poorer prognosis in Japan, 
where cardiac involvement may be as high as 58% in Japanese patients with sarcoidosis
7,8)
  and 
may be responsible for as many as 85% of deaths of Japanese patients with the disease.
8,9)
 
CS frequently presents as asymptomatic cardiac involvement and is only evident by 
abnormalities on ECG, echocardiography or cardiac magnetic resonance imaging (CMRI).
2)
  
Clinically, CS commonly presents with congestive heart failure (CHF), often associated with a 
dilated cardiomyopathy (DCM)-like phenotype. CS also commonly presents with electrical 
abnormalities, including conduction disturbances,
4)
  and serious ventricular arrhythmias (VA), 
that include both ventricular tachycardia (VT) and ventricular fibrillation (VF).
10)
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Although the etiology and exact pathophysiology of sarcoidosis, including cardiac 
involvement, are still not fully understood, the inflammatory nature of the disease resulted in 
offering corticosteroid treatment as a therapeutic option for patients with CS.
11-13)
  Despite the 
long term and frequent use of corticosteroid, there is still controversy about their proper timing,
3)
  
proper dosing,
14)
  and their clinical efficacy, particularly in patients with advanced cardiac 
dysfunction 
15,16)
  and VA
17-20)  
are not fully evaluated.  Corticosteroid treatment favorably 
affects prognosis of CS patients, furthermore, significant improvement of prognosis of CS 
patients as compared to older registries that had lower rates of steroid use was also 
documented.
3,4,13)
  Steroid treatment became a cornerstone therapy for CS once cardiac 
involvement is strongly suspected or established, but in the last decade, no other agents, including 
immunosuppressive drugs, has been proved to be more effective in controlling inflammation in 
CS. 
On the other hand, left ventricular (LV) systolic dysfunction, defined as a LV ejection 
fraction (LVEF) <50%, as documented with other forms of structural heart disease, was found to 
be a marker of poor prognosis in Japanese CS patients despite steroid treatment.
3)
  Furthermore, 
advanced LV dysfunction (LVEF <30%) in CS patients at time of presentation represented 
advanced LV remodeling that was irreversible after steroid treatment as compared to those with 
LVEF >30%, reflecting advanced myocardial scarring with little or no role of active inflammation 
at this stage.
21)
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The latest study to address the prognosis of a Japanese steroid-treated CS population was 
the work of Yazaki et al. in 2001.
3)
  Since then, the increased use of novel and effective therapies 
for conditions such as VA, sudden cardiac death (SCD) and CHF, including drugs and devices, 
has greatly improved the prognosis and survival of patients in the context of various structural 
heart disease etiologies, and whether this will have similar impact on prognosis and survival of 
CS patients remains to be identified.   
Therefore, it was our aim through this study to re-explore the natural history of Japanese 
steroid-treated CS patients, and to examine whether prognosis of this population has improved 
over time, and whether the prognostic markers of the disease have changed over the last decade. 
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Methods 
Patient Selection 
From 61 consecutive patients who were found to have a definite diagnosis of CS at Tohoku 
University Hospital between April 2002 and March 2012, we excluded 3 patients for not receiving 
steroid treatment upon diagnosis, and we included the remaining 58 steroid-treated patients in our 
analysis (figure 1).  The reason of not using steroid upon diagnosis in these patients include 
refusal of receiving the drug by one patient and very limited myocardial involvement on CMRI 
with uneventful courses in the other two.  The three patients are under close surveillance with 
uneventful courses on follow up.  The clinical data of the 58 patients who were included in the 
analysis were obtained from the detailed database of cardiology department of Tohoku University 
Hospital, including demographic, clinical, laboratory, imaging, procedural and interventional data, 
both at time of primary presentation, as well as their follow-up data. 
 
Diagnosis of Cardiac Sarcoidosis 
The revised guidelines for diagnosis of cardiac sarcoidosis from the Japanese Ministry of Health 
and Welfare were used (table 1).
 22)
  The diagnosis of CS was made either directly by 
endomyocardial biopsy or indirectly by clinical evidence of cardiac involvement on a background 
of biopsy-proven extra-cardiac sarcoidosis, using ECG findings and cardiac imaging tests that 
included echocardiography, scintigraphy and cardiac magnetic resonance imaging (CMRI).  
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Study Variables 
I retrospectively examined the baseline clinical, laboratory, and imaging variables, of my 
population. CS patients were sub-divided according to their baseline loading prednisolone dose 
received upon diagnosis, and were categorized as those started on a dose < 30 mg/day and those 
started on a dose of > 30 mg/day.  
 Demographic and clinical data: 
They include age, gender, presence of extra-cardiac sarcoidosis, heart rate (HR), New York Heart 
Association (NYHA) functional class.  Electrical abnormalities were detected either by ECG 
monitoring during admission or later diagnostic evaluation with 12-lead ECG, Holter ECG, or 
device recording.  VA in this study included sustained VT and aborted sudden cardiac death 
(SCD) due to VF, and the included beats of ventricular origin, at a rate of more than 100 
beats/min,
23)
  that do not resolve spontaneously and/or last more than 30 seconds. Beats of 
ventricular origin not fulfilling these conditions were not included.   
 
 Laboratory data: 
Laboratory data included brain natriuretic peptide (BNP) level and soluble interleukin 2 receptor 
(IL-2R) level.  Impaired BNP was defined as serum BNP level > 100 pg/ml.  Both baseline 
BNP levels and levels after 1 year of starting steroid therapy were measured and reported, and 
their correlations with prognosis were individually evaluated.  
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 Imaging data: 
1. Transthoracic echocardiography was performed to evaluate LV indices including LV 
end-diastolic and end-systolic diameters, left atrial dimensions, and LVEF.  LVEF was 
measured by M-mode using Teichholz method and formula.
24) 
 Modified Simpson’s method 
(disc method) was used in the presence of LV dyssynchrony.
25)
  Impaired LVEF was 
defined as LVEF < 50%.  Both baseline LVEF and LVEF after 1 year of starting steroid 
treatment were measured and reported, and their correlations with prognosis were 
individually evaluated. 
 
2. CMRI was performed before starting corticosteroid therapy and after patients had been 
clinically stable after heart failure or arrhythmia.  We used the standard protocol for cardiac 
MRI in our institution,
26)
  and ECG-gated magnetic resonance (MR) images were obtained 
in all patients during breath-holding on a 1.5-T imager (Magnetom Vision, Siemens Medical 
Solutions, Erlangen, Germany; Achiva, Philips Medical Systems, Best, The Netherlands) 
using a body array coil (Siemens) or a five-channel cardiac coil (Philips).  To evaluate LV 
anatomy, cine MR images of the LV in one horizontal, one vertical long, and five short axis 
slices were obtained.  Delayed contrast-enhanced MR images using inversion 
recovery-prepared gradient-echo sequence were acquired 10-15 minutes after the injection of 
gadopentetate dimeglumine (0.15 mmol/kg) in the same plane as cine imaging with the 
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Siemens Scanner or in 10 horizontal, 10 vertical long and 20 short axis slices with the 
Philips scanner.  The acquisition parameters of the delayed contrast-enhanced MR images 
were 3.7-7.5/1.2-3.4; flip angle, 15°; field of view, 380 mm; matrix, 182-224 × 139-256; and 
slice thickness, 5 mm.  The inversion time (200–300 milliseconds) was adjusted to null 
signal from normal myocardium.  CMRI was performed in 37 out of the 58 CS patients, 
and prior device implantation was the reason for contraindication in the remaining 21 
patients. 
  
Study Endpoints 
The primary endpoint was a composite outcome composed of VA, heart failure (HF) 
hospitalization, de-novo device therapy, and all-cause death.  Secondary endpoints included the 
separate evaluation of VA, HF hospitalization, device therapy, and all-cause death, either studied 
in survival analysis, or studied in the process of describing their temporal trends following the 
initiation of steroid therapy in our CS population. 
 VA was previously defined and mode of detection reported.  HF hospitalization was 
considered according to the index admission diagnosis in patients file as reported by first treating 
cardiologist.  Only de-novo device implantation was considered because indications of later 
device management are confounded by issues unrelated to the natural history of CS, including 
management of system-related complications as well as battery exchange.    
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Statistical Analysis 
Continuous variables were expressed as mean ± SD.  Categorical data were presented as 
percentage and frequency.  Differences between groups were compared by Student t-test (for 
normally distributed variables) and Mann-Whitney test (for non-normally distributed variables) 
for continuous variables.  The chi-square test was used for categorical variables and the Fisher 
exact test for those instances in which the expected cell count was <5.  Event rates of endpoints 
were expressed as unadjusted Kaplan-Meier estimates and a Cox proportional hazard test was 
used for univariate and multivariate analysis of the interaction between patient characteristics and 
study endpoints.  All statistical tests were 2-tailed, and a P value <0.05 was considered to be 
statistically significant.  All analysis was performed using SPSS software (version 18, SPSS, 
Chicago, Illinois).  
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Results 
General Characteristics 
The baseline clinical characteristics of the 58 patients with CS at presentation are shown in table 
2.  They were characterized by middle-age and more female, and 86% of them had extra-cardiac 
involvement of sarcoidosis, with only 17% of them having positive diagnostic cardiac biopsy.  
The prevalence of hypertension, diabetes mellitus, coronary artery disease and smoking was 
relatively low.  No clinical or echocardiographic evidence of structural heart disease was noted 
in almost half of CS patients (49%), with 27% of patients showing a picture of dilated LV and 
cardiac dysfunction indistinguishable from the idiopathic form, and the remaining 24% showing 
isolated ventricular septal thinning that is characteristic of cardiac involvement in sarcoidosis.  
Most of the patients were in NYHA class I (52%) or II (29%), with less frequency of presenting 
with class III or IV (16% and 3% respectively).   
Advanced heart block was the most common electrical abnormality encountered at baseline 
(41%), and VA collectively was the second most common electrical abnormality (31%), where 
NSVT was noted in 19% and VT/VF in 24%.  Laboratory data were normal apart from modest 
elevation of BNP (325 pg/ml).  Also echocardiographic parameters were within normal range 
with borderline mean LVEF (50 %).  Importantly, LGE-CMRI at baseline examination was 
noted in 70% of the 37 CS patients tested.  Other than prednisolone, drugs blocking the 
renin-angiotensin system, angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin 
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receptor blockers (ARBs), were the most commonly used group of drugs in CS patients (57%) 
followed by beta blockers (BBs) in this population (46%). Amiodarone was administered to 7% of 
the patients in this cohort. 
 
Steroid Treatment and Event Trend  
The vast majority of our CS population (52 patients) received the conventional established 
prednisolone dose of 30 mg/day (either daily 30 mg or 60 mg every other day) or less, and only 6 
patients were loaded with a prednisolone dose > 30mg/day.   
As shown in table 3, there were no statistically significant differences in patients’ 
characteristics between CS patients according to their initial prednisolone dose, apart from 
significantly higher levels of soluble Interleukin-2 receptor (IL-2R) levels among patients started 
on the higher dose.  However, there was a uniform insignificant trend of more severe disease 
parameters in patients receiving a higher initial steroid dose, including higher incidence of VA, 
higher baseline BNP, lower LVEF and larger LV dimensions. 
Figure 2 shows that there is a uniform trend of incident events in CS patients after starting 
steroid therapy as regards VA, HF hospitalizations, device therapy, and the primary composite 
endpoint (figures 2A, 2B, 2C, and 2D respectively), in the form of relatively high event rate at the 
outset of therapy, followed by steady state of relatively low event rate that continues across the 
first 3 years of therapy.  Beyond the third-post treatment year, VA and device therapy remained 
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relatively low, while HF hospitalization and composite events showed a second rise of events.  
 
Prognosis and Prognostic Indicators in CS patients 
In the median follow-up period of ~50 months (18-120 months), and as shown in table 4, VA 
events, HF hospitalizations, and the composite endpoint occurred in 31%, 22% and 48% of CS 
patients respectively.  Only two death events occurred in our population, the first of which 
occurred after 56 months, and the second after 75 months of follow-up respectively. Estimated 3-, 
5- and 10-years survival was 100%, 98% and 96% respectively (figure 3).   
Kaplan-Meier analysis in figure 4 showed conventional prognostic indicators in patients 
with CS and their effect on outcome.  Steroid-treated CS patients with baseline LVEF < 50% 
were shown to have significantly worse prognosis than those with preserved baseline LV systolic 
function, while a higher initial prednisolone dose >30 mg/day was not found to predict better 
event-free survival in CS patients as compared to regular dose of 30mg/day (figures 4A and 4B, 
P<0.001 and P=0.76 respectively). 
As for novel predictors of prognosis studied in this research, a LVEF > 50% after 1 year of 
steroid therapy was found to predict better prognosis in CS patients, while a normal BNP level < 
100 pg/ml after 1 year of steroids did was not found to be similarly protective (figures 5A and 5B, 
P=0.03 and 0.24 respectively). 
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Figure 6 also shows the effect of another novel marker in this disease entity, which is the 
presence of LGE-CMRI at baseline, on the prognosis of CS patients in terms of both 
composite-endpoint and VA (figures 6A and 6B respectively), where it was found to be a 
significantly associated with poor composite event-free survival (P= 0.03).  Although it did not 
reach statistical significance, there was a strong trend of higher VA events in patients with 
LGE-CMRI at baseline. Furthermore, the lack of LGE-CMRI at baseline carried a 100% negative 
predictive value of events, whether composite or VA, in steroid-treated CS patients, and as seen 
from two representative LGE-CMRI images of two CS cases in figure 7, where the first case with 
absence of LGE-CMRI (figure 7A) ran an uneventful course after starting steroid therapy as was 
the case with all cases with similarly negative LGE-CMRI at baseline.  Patients with 
LGE-CMRI at baseline were at higher risk of events, particularly VA (figure 7B), despite steroid 
therapy.     
Table 5 shows that univariate predictors of poor outcome in our population were the 
presence of VA at baseline (HR=2.4, P=0.02) and depressed 1 year post-steroid LVEF (HR 2.2, 
P=0.03).  Adjusted multivariable analysis confirmed baseline VA (HR=2.9, P=0.02), and 1 year 
post-steroid LVEF (HR=2.3, P=0.03) as predictors of poor outcome, in addition to baseline LVEF 
(HR=2.2, P=0.04).  LGE-CMRI was not included in the analysis due to lack of events in the 
negative arm. 
          
14 
 
Discussion 
The main findings of the present study are; 1) Japanese steroid treated CS patients has favorable 
prognosis in the modern era, and 2) that depressed LVEF at baseline and on follow-up, the 
presence of VA, and the presence of LGE-CMRI at baseline are independent markers of poor 
prognosis in this population. 
  
Prevalence and Diagnosis of CS  
The prevalence of sarcoidosis, as well as the incidence of cardiac involvement are both relatively 
high in Japan,
2,27)
  reaching ~ 60% of sarcoidosis patients in some series.
8)
  This offers a unique 
chance to study various unstudied aspects of this disorder.  Furthermore disease burden in 
Japanese patients seems to be particularly high, where cardiac involvement may be responsible 
for as many as 85% of deaths of Japanese patients with the disease.
8,9)
 
Although it was previously shown that the majority of western CS patients are young adults 
between the ages of 20~40 without a definite sex predominance,
5)
  the present study shows that 
the majority of the Japanese CS patients are middle-aged females, a consistent finding with the 
previous studies in Japan.
3,28)
  These results suggest some racial differences in demographic 
characteristics of CS patients that might extend to presentation and prognosis of the disorder.  
Most of the CS patients in the present study were diagnosed in conjunction with involvement of 
other organs, again, a consistent finding with the previous study in Japan.
29)
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Most CS patients in the present study showed no evidence of structural cardiac abnormality 
when assessed by echocardiography with a similar prevalence rate as in western studies with 
14~31% prevalence rate,
30,31)
 thus highlighting the limited sensitivity of echocardiography in this 
subset of CS patients.
32)
  In CS patients, the usual echocardiographic abnormality, if present, is a 
DCM-like phenotype (reduced LVEF and regional or global LV hypokinesia) that is difficult to 
distinguish from the idiopathic form,
2,27,32)
 which also was the case in the present study.  Indeed, 
echocardiography has a low specificity for diagnosis of CS
32)
 and its main value lies in its ability 
to predict poorer prognosis of CS patients, as LV dilatation is an established predictor of 
mortality.
3)
  Although an appearance similar to hypertrophic cardiomyopathy (HCM) has been 
described in limited case series,
33)
 we did not come across any patient with such a phenotype in 
the present study.   
 
Steroid Treatment and Events Trend 
The optimal dose of steroid treatment in CS is not known or studied, and requires balancing the 
risk of side effects with the likelihood of response.
34) 
 So using 30 mg/day as the cut-off point 
was based mainly upon consensus in the medical Japanese society of using no more than 30 mg 
day as a loading for CS, and supported by a single retrospective analysis stating that higher doses 
offers no additional benefit in terms of survival in Japanese CS patients.
3)
  That is why, 
compared to this older study, I reported marked decrease in the frequency of use of the larger 
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loading dose (> 30 mg/day) from 40% in the work of Yazaki et al.
3) 
to only 10% in this study 
despite continued lack of supportive evidence for superiority of such a higher dose.  Although 
the obvious difference of the number between two groups is a limitation in this study, it was 
interesting to see that there is still some clinical trend to use it among patients with poorer 
presentations, as seen from the worse LV indices and significantly higher inflammatory burden, as 
evident by the significantly higher levels of soluble IL-2R levels, among patients chosen for such 
a starting dose.  
Steroid treatment has also shown success in reducing various event rates after the early 
loading period, compared to very early high event rates during the loading period, after which 
event rates remained fairly low for around 3 years.  The composite event rate, however, showed 
a second rise of event rate after the third year, mainly secondary to increase in HF events, which 
reflects the steadily progressive natural history of the disease when advanced heart failure and 
extensive myocardial fibrosis occur and the role of inflammation becomes minimal.
35)
  Although 
tachyphylaxis is well documented with topical steroids, no reports of a similar response with 
systemic use are yet reported,
36)
 and thus unlikely to be the cause of such a second rise of HF 
events. 
 
Prognosis and Prognostic Indicators of Japanese CS Patients  
In our study we came across only two death events, the first of which was just 4 months before 
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the fifth year of follow-up, and the second occurred between the sixth and seventh years of 
follow-up, and 3, 5, and 10-years survival were estimated to be 100%, 98% and 96% respectively,  
indicating very favorable survival and marked improvement in terms of mortality in Japanese CS 
patients in the modern era, as compared to a very similar Japanese steroid-treated CS cohort 
studied by Yazaki et al. in 2001, where 3, 5, and 10-years survival were estimated to be 82%, 75%, 
and 61% respectively.
3)
  This may be explained by the increased use of evolving therapies 
targeting morbid conditions that accompany cardiac involvement in sarcoidosis patients, such as 
VA, SCD and HF.  Increased use of protective agents might theoretically account for such 
improvement in survival, and this evident from increased use of angiotensin-converting enzyme 
inhibitors from 21% in the work by Yazaki et al.
3)
 to 57% in this cohort.  However, similar trends 
with other agents, especially beta-blockers, are not known due to lack of frequency of its use in 
the work of Yazaki et al.
3)
   
More importantly is the prominent role of device therapy, where strong evidence from major trials 
in patients with ischemic heart disease and DCM, showed considerable survival benefits of 
implantable cardioverter- defibrillators (ICD),
37-39)
 and cardiac resynchronization therapy (CRT), 
with or without defibrillator capabilities.
 40-42)
  This body of evidence resulted in recommending 
ICD as a class 1 indication for primary and secondary prevention of SCD due to VA in both 
European (ESC) and US (ACC/AHA) guidelines issued in 2005,
43,44)
 and CRT was also 
recommended for use in patients with ischemic and dilated cardiomyopathy in US (ACC/AHA) 
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guidelines issued in the same year.
44)
  Furthermore, despite lack of specific statistics about their 
use in the work by Yazaki et al.,
3)
 the authors of that research reported limited use of ICD in their 
cohort, as compared to a considerable implantation rate in my study.  Furthermore, they reported 
the total lack of any CRT device implantation in any patient in the cohort, supporting the possible 
interplay between device management and improved prognosis of CS patients in the modern era. 
Due to improved prognosis and small number of events, we studied a primary composite 
endpoint including VA, HF hospitalization, de-novo device implantation and all-cause death as a 
surrogate of prognosis in CS patients.  Independent predictors of poor outcome in our study 
included depressed LVEF at baseline and/or on follow-up, VA, and positive LGE-CMRI. LV 
systolic dysfunction is well-established as a marker of poor prognosis in various forms of 
structural heart disease, and is a well-established prognosticator in CS ptients.
3)
  This is 
explained by higher mortality, frequent heart failure hospitalization, and higher incidence of VA,
 
45-48)  
as was the case in our study.  Interestingly, depressed LVEF on follow up and failure to 
improve after steroid therapy also predicted poorer prognosis.  This is probably explained by 
higher myocardial scar burden that is irreversible with anti-inflammatory therapy, hallmarking 
more advanced disease.  This marker has been recently verified to predict prognosis after 
primary revascularization in patients with acute myocardial infarction and in patients with 
advanced heart failure with CRT.
49-51)
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The presence of sustained VT/VF on presentation predicted poorer outcome in CS, as the 
case with other forms of structural heart disease.  VA itself is known to be the strongest predictor 
of subsequent VT/VF, as reported by secondary prevention studies of ICD.
52,53)
  Furthermore, we 
previously reported that CS patients with VA at presentation have more compromised LV function 
indices than those without, 
54)
 and as mentioned earlier, this might add another reason for why 
such patients run a less favorable course. 
LGE-CMRI significantly predicted poorer outcome in CS patients.  This finding is also 
supported by the role of CMRI as a risk stratification method for adverse prognosis in various 
forms of structural heart disease, owing to its unique ability to accurately detect and delineate 
myocardial fibrosis, the presence and extent of which have become well established markers of 
poorer prognosis,
55-59)
 whether detected by histopathology
60)
 or LGE-CMRI,
57,58) 
and was even 
related to poor prognosis in the general population.
61)
   
The presence of LGE-CMRI at baseline was also specifically found to be linked to higher 
VA events in CS patients on follow up despite steroid treatment.  Bello et al. reported that scar 
burden was a significant predictor of VT inducibility, whereas LVEF was not.
55)
  It has been 
recently shown that patients with advanced cardiomyopathy and ICD with proven myocardial 
fibrosis by LGE-CMRI have a high likelihood of appropriate ICD therapy.
62)
  Although 
scar-based-reentry has been thought to account for VA only in patients with ischemic 
cardiomyopathy, accumulating evidence suggests that reentry appears to play a major role in the 
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mechanism of sustained monomorphic VT in this patient population.
63)
  Furthermore, it has been 
recently demonstrated that programmed electrical stimulation predicts appropriate ICD therapy 
used for primary prevention of SCD only in patients with evidence of cardiac involvement on 
CMRI or positron emission tomography,
64)
 suggesting the possible importance of LGE-CMRI for 
risk stratification for VA and SCD in CS patients. 
Importantly, patients without LGE-CMRI showed an uneventful course, and this perfect 
negative predictive value not only enforces its role in predicting adverse outcome in this 
population, but also stands out as a unique diagnostic criterion for CS in patients with 
extra-cardiac involvement.  The present findings may be useful for the revision of the role of 
LGE-CMRI as a potential major diagnostic criterion for diagnosis of CS in the Japanese Ministry 
of Health and Welfare guidelines.
22)
  
 
Study Limitations 
Several limitations should be mentioned for the present study.  First, our study has the inherent 
limitations of retrospective analysis.  Thus, the present findings should be confirmed in a future 
prospective study.  Second, not all CS patients underwent CMRI test.  This was inevitable as 
device implantation was the reason for contraindication in most cases without CMRI study.  
However, although not reported, the clinical characteristics and long-term prognosis were 
comparable between the patients who underwent CMRI study and those who did not, so the 
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present findings may not be biased in regarding this point.  Third, the definitions of favorable 
LVEF and BNP courses were largely arbitrary due to lack of established definition for dynamic 
shifts in these variables.  Fourth, evaluation of LVEF was mainly performed using Teichholz 
formula, which is known to have limitations and poor correlation with more recent modalities and 
methods in the presence of significant dyssynchrony or LV wall motion abnormalities; however, 
this was partially overcome in this study by using the modified Simpson’s method in such in the 
presence of such conditions.  Finally, the study was a single center experience, and was 
underpowered with little number of mortality events to be able to evaluate mortality as a separate 
endpoint.  Thus, this point needs to be evaluated in a future study with a large number of patients 
in multi-center effort to be more informative and more representative of Japanese CS patients.      
 
Conclusions 
In the present study, we were able to demonstrate that a the prognosis of Japanese steroid-treated 
CS patients has improved in the modern era, and that the presence of VA, depressed LVEF at 
baseline and/or after 1 year of therapy, and LGE-CMRI are considered as independent predictors 
of poor prognosis in CS patients.  
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Figure Legends 
 
Figure 1. Flow Diagram for Study Population.  
 
Figure 2. Temporal trends of Events in Steroid-treated Cardiac Sarcoidosis Patients. 
There is uniform trend of an exceptional and brief high rate of cardiovascular events in the early 
post-treatment months, followed by a relatively low event rate within the first 3 post-treatment 
years.  Some events continues to run a stable course extending beyond the third post-treatment 
year as with ventricular arrhythmias (2A), and device therapy (2C), while in the case of heart 
failure hospitalizations (2B) and composite events (2D), there is a trend of re-rise of event rate 
after the third post-treatment year.  
 
Figure 3. Overall survival of Steroid-Treated Cardiac Sarcoidosis Patients. 
Survival rates of cardiac sarcoidosis patients since the start of steroid treatment were 100% at 1 
and 3 years, 98% at 5 years, and 96% at 10 years.  
 
Figure 4. Traditional Prognostic Indicators and Composite Endpoint-Free Survival in 
Steroid-Treated Cardiac Sarcoidosis Patients. 
Kaplan-Meier curves for composite endpoint-free survival in CS patients.  (A) Patients with 
baseline LVEF > 50% (blue line, n=38) had better event-free survival rate than patients with 
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baseline LVEF < 50% (red line, n=20) (P< 0.001)).  (B) Composite endpoint-free survival was 
comparable between patients with conventional initial prednisolone dose < 30 mg/day (blue line, 
n=52) and those with higher initial prednisolone dose > 30 mg/day (red line, n=6) (P=0.76).  
  
Figure 5. Novel Prognostic Indicators and Composite Endpoint-Free Survival in 
Steroid-Treated Cardiac Sarcoidosis Patients. 
Kaplan-Meier curves for composite endpoint-free survival in CS patients.  (A) After 1 year of 
steroid therapy, patients with LVEF > 50% (blue line, n=33) had better event-free survival rate 
than patients with baseline LVEF < 50% (red line, n=25) (P= 0.03).  (B) Patients with BNP < 
100 pg/ml after 1 year of steroid therapy (blue line, n=43) had insignificant trend of better 
composite endpoint-free survival than patients with BNP > 100 pg/ml (red line, n=15) (P= 0.24).   
 
Figure 6. Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging and 
Prognosis of Steroid-Treated Cardiac Sarcoidosis Patients. 
Kaplan-Meier analysis for prognosis of steroid-treated CS patients according to the presence of 
baseline LGE-CMRI.  (A) Patients with no LGE-CMRI (blue line, n=11) had no reported 
composite endpoint events after steroid therapy as compared to significantly higher event rate in 
patients with positive LGE-CMRI (red line, n=26) (P< 0.01).  (B) There were also no reported 
events of VA in CS patients without baseline LGE-CMRI (blue line, n=11), unlike multiple VA 
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events among the LGE-CMRI positive arm (red line, n=26), however, this trend did not reach 
statistical significance (P= 0.12) 
 
Figure 7. Cardiac Magnetic resonance Imaging of Steroid-Treated Cardiac Sarcoidosis 
Patients. 
CMRI depicting LV in short axis view of two steroid-treated CS patients.  (A) Lack of 
LGE-CMRI in a 55 year old female patient with pulmonary sarcoidosis presenting with fatigue, 
premature ventricular beats, and positive cardiac gallium uptake at LV free wall, but with 
unremarkable course since the start of steroid treatment.  (B) Evidence of LGE-CMRI in the 
sub-epicardial layer of the anterior LV wall (multiple small white arrows) in a 41 year-old male 
patient diagnosed with CS on the background of a pre-existing pulmonary sarcoidosis, presenting 
with recurrent sustained monomorphic VT despite steroid therapy.  
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Figure 3 
 
 
 
Months 20 40 60 80 100 120 
Number at risk 58 48 34 19 11 5 
Censored 10 14 14 7 6 5 
Deaths 0 0 1 1 0 0 
Cum. Survival 100 100 98% 96% 96% 96% 
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Table 1: Revised guidelines for diagnosing cardiac sarcoidosis 2006 
(Japan Society of Sarcoidosis and Other Granulomatous Disorders) 
1. Histologic diagnosis group 
Cardiac sarcoidosis is confirmed when myocardial biopsy specimens demonstrate 
non-caseating epithelioid cell granuloma with histological or clinical diagnosis of 
extra-cardiac sarcoidosis 
2. Clinical diagnosis group 
Although myocardial biopsy specimens do not demonstrate non-caseating epithelioid cell 
granuloma, extra-cardiac sarcoidosis is diagnosed histologically or clinically and satisfies the 
following conditions and more than one in six basic diagnostic criteria 
(1) More than 2 of 4 major criteria are satisfied 
(2) One in 4 major criteria and more than 2 in 5 minor criteria are satisfied 
Major Criteria 
(a) Advanced AV block. 
(b) Basal thinning of the interventricular septum. 
(c) Positive cardiac 67Ga uptake. 
(d) Depressed ejection fraction of the left ventricle (LVEF<50%). 
Minor Criteria 
(a) Abnormal ECG findings: Ventricular arrhythmias (VT, multifocal or frequent PVCs), 
CRBBB, axis deviation or abnormal Q-wave. 
(b) Abnormal echocardiography: Regional abnormal wall motion or morphological 
abnormality (ventricular aneurysm, wall thickening). 
(c) Nuclear medicine: Perfusion defect detected by 201Tl myocardial scintigraphy or 99Tc 
myocardial scintigraphy. 
(d) Gd-enhanced MRI: Delayed enhancement of myocardium. 
(e) Endomyocardial biopsy: Interstitial fibrosis or monocyte infiltration over moderate grade. 
AV: atrioventricular; CRBBB: Complete right bundle branch block; ECG: electrocardiogram; 
MRI: magnetic resonance imaging; PVCs: premature ventricular contractions; VT: 
ventricular tachycardia  
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Table 2: Patients Characteristics at Baseline 
Variables All patients (n= 58) 
Age (years) 57±12 
Gender (M/F) 15/43 
Extra-cardiac sarcoidosis present  50 (86) 
Hypertension  14 (24) 
Diabetes mellitus 14 (24) 
CAD  2 (3) 
Dyslipidemia 23 (39) 
Smoking   
  Non-smoker 47 (81) 
  Ex-smoker 5 (9) 
  Current smoker 6 (10) 
Cardiac phenotype (by echocardiography)  
  Normal 28 (49) 
  DCM-like 16 (27) 
  Isolated septal thinning 14 (24) 
Clinical data  
  Heart rate (beats/min)
 
71±14 
NYHA class  
    I 30 (52) 
    II 17 (29) 
    III 9 (16) 
    IV 2 (3) 
Electrical abnormalities  
  Ventricular arrhythmias  18 (31) 
    Non-sustained VT 11 (19) 
     VT/VF 14 (14) 
  Advanced heart block 24 (41) 
  Sick sinus syndrome 1 (2) 
  AF 7 (12) 
  Supraventricular tachycardia 1 (2) 
Laboratory data  
  Hemoglobin (g/dl) 13±1.7 
  Serum creatinine (mg/dl) 0.8±0.3 
  Triglyceride (mg/dl) 138±72 
  Total cholesterol (mg/dl) 205±35 
  Brain Natriuretic Peptide (pg/ml) 325±515 
Echocardiographic parameters  
  LVEF (%) 50±16 
  LVDs (mm) 37±12 
LVDd (mm) 52±8 
  LAD (mm) 35±6 
Positive biopsy 10 (17) 
LGE-CMRI (present/absent) 26/11 
Drugs  
-blockers 27 (46) 
ACE-I/ARBs 33 (57) 
Statins 17 (29) 
Amiodarone 4 (7) 
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Results are presented as either mean±SD or number of patients (%).   
ACE-I, Angiotensin converting enzyme inhibitors; AF, atrial fibrillation; ARBs, Angiotensin 
receptor blockers; BNP, brain natriuretic peptide; CAD, coronary artery disease; DCM, dilated  
cardiomyopathy; LAD, left atrial dimensions; LGE-CMRI, late gadolinium enhancement on 
cardiac magnetic resonance imaging; LVDs/LVDd, end-systolic/end-diastolic left ventricular 
dimensions; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VF, 
ventricular fibrillation; VT, ventricular tachycardia. 
The results on LGE-CMRI were obtained from 37 patients without device therapy.   
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Table 3: Patient Characteristics by Initial Steroid Dose  
Variables 
Steroid Dose < 
30 mg 
(n=52) 
Steroid Dose > 
30 mg 
(n= 6) 
P-value 
 Age (years) 57 ± 12 57 ± 12 0.29 
 Gender (M/F) 14/38 2/4 0.53 
 Advanced heart block 21 (40) 2 (33) 0.55 
 Ventricular arrhythmia 24 (46) 5 (83) 0.09 
DCM-like phenotype 16 (30) 4 (66) 0.10 
 Heart rate (beats/min) 71 ± 13 77 ± 13 0.35 
 NYHA class     
0.17 
    I   27 (52) 4 (66) 
    II 16 (30) 1 (17) 
    III 8 (16) 0 (0) 
    IV 1 (2) 1 (17) 
 IL2R 624 ± 287 1651 ± 1775 0.003 
 Baseline BNP (pg/ml) 236 ± 453 438 ±564 0.31 
Favorable BNP course 38 (73) 5 (83) 0.51 
Echocardiographic indices       
     LVEF 50 ± 16 39 ± 12 0.14 
    LVDd (mm) 51 ± 8 58 ± 9 0.11 
    LVDs (mm) 36 ± 12 47 ± 9 0.08 
  Favorable LVEF course 32 (61) 1 (17) 0.04 
 LGE-CMRI (present/absent) 20/11 6/0 0.22 
Results are presented as either mean±SD or number of patients (%).   
Abbreviations as in table 2.   
The results on LGE-MRI were obtained from 37 patients without device therapy.  
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Table 4: Event Rates in Japanese Steroid-treated Cardiac Sarcoidosis Patients 
Endpoints 
Cumulative events 
3 years  5 years  10 years 
n %   n %   n %  
All-cause 
death 
0 0  1 2  2 4 
Ventricular 
arrhythmia 
14 24  16 27  18 31 
HF 
hospitalization 
3 5  7 12  13 22 
Composite 
events* 
21 36  26 45  28 48 
* Includes all-cause death, heart failure hospitalization, ventricular arrhythmia and device 
therapy 
HF, heart failure 
 
 
Table 5: Proportional Hazard Analysis of Prognostic Indicators of Composite 
Endpoints in Patients With Cardiac Sarcoidosis 
Variables 
Univariate  Multivariate* 
HR (95% CI) P-value  HR (95% CI) P-value 
Extra-cardiac 
sarcoidosis 
0.71 (0.30-1.69) 0.45  -- -- 
Initial steroid dose > 30 
mg/day 
0.81 (0.26-2.57) 0.73  -- -- 
LVEF < 50% 2.09 (0.98-4.46) 0.06  2.27 (1.04-4.97) 0.04 
VA at baseline 2.41 (1.14-5.07) 0.02  2.98 (1.17-7.59) 0.02 
Unfavorable LVEF course   2.27 (1.06-4.86) 0.03  2.32 (1.07-4.99) 0.03 
Unfavorable BNP course 1.40 (0.62-3.17) 0.41  1.43 (0.55-3.73) 0.45 
* Adjusted for age, gender, presence of extra-cardiac sarcoidosis, initial steroid dose, 
hypertension, diabetes mellitus, and drug treatment     
CI, confidence interval; HR, hazard ratio; other abbreviations as in table 2. 
  
